Araclon Biotech at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

Araclon Biotech takes part in 2 sessions at CTAD 2026 in Boston. Its program centres on blood biomarker assays, including a plasma GFAP test. Its work covers multimarker strategies to shrink the diagnostic grey zone of p-tau217 results.

OrganizationCTAD 2026 Attendance
Araclon Biotech
Zaragoza, Spain
araclon.com
Biomarker & diagnostics companies
Grifols subsidiary developing blood-based amyloid-beta assays for Alzheimer's diagnosis and ABvac40, an amyloid-beta vaccine.
Poster
Wed Nov 18
7:15am–5:30pm
Poster
Wed Nov 18
7:15am–5:30pm

Explore the full CTAD 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full CTAD 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Araclon Biotech

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction